KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Minority Interest (2017 - 2025)

Amneal Pharmaceuticals has reported Minority Interest over the past 9 years, most recently at $77.3 million for Q4 2025.

  • Quarterly results put Minority Interest at $77.3 million for Q4 2025, up 18.96% from a year ago — trailing twelve months through Dec 2025 was $77.3 million (up 18.96% YoY), and the annual figure for FY2025 was $77.3 million, up 18.96%.
  • Minority Interest for Q4 2025 was $77.3 million at Amneal Pharmaceuticals, up from $67.8 million in the prior quarter.
  • Over the last five years, Minority Interest for AMRX hit a ceiling of $77.3 million in Q4 2025 and a floor of $13.1 million in Q1 2021.
  • Median Minority Interest over the past 5 years was $34.6 million (2023), compared with a mean of $39.4 million.
  • Biggest five-year swings in Minority Interest: increased 4.11% in 2021 and later soared 79.51% in 2023.
  • Amneal Pharmaceuticals' Minority Interest stood at $16.9 million in 2021, then surged by 47.57% to $24.9 million in 2022, then skyrocketed by 65.51% to $41.3 million in 2023, then soared by 57.35% to $65.0 million in 2024, then rose by 18.96% to $77.3 million in 2025.
  • The last three reported values for Minority Interest were $77.3 million (Q4 2025), $67.8 million (Q3 2025), and $65.8 million (Q2 2025) per Business Quant data.